Vanda Pharmaceuticals announced that the U.S. Patent and Trademark Office has issued a notice of allowance for its Ponvory patent application, number 17/962,968, covering methods for reducing clinical management events before or during the treatment of multiple sclerosis and methods for reinitiating treatment after missed doses. When issued, this patent is anticipated to expire on October 10, 2042. Upon issuance, Vanda intends to list this patent in the FDA publication Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VNDA:
- Vanda Pharmaceuticals’ IND application for VCA-894A granted FDA approval
- Vanda Pharmaceuticals says court denied in part U.S. motion to dismiss
- Vanda announces publication of journal article on Fanapt study
- Vanda comments on FDA’s recently announced guidance on communication
- Vanda Pharmaceuticals acquires U.S. and Canadian rights to PONVORY
